CA2289476A1 - Modified tnf.alpha. molecules, dna encoding such modified tnf.alpha. molecules and vaccines comprising such modified tnf.alpha. molecules and dna - Google Patents

Modified tnf.alpha. molecules, dna encoding such modified tnf.alpha. molecules and vaccines comprising such modified tnf.alpha. molecules and dna Download PDF

Info

Publication number
CA2289476A1
CA2289476A1 CA002289476A CA2289476A CA2289476A1 CA 2289476 A1 CA2289476 A1 CA 2289476A1 CA 002289476 A CA002289476 A CA 002289476A CA 2289476 A CA2289476 A CA 2289476A CA 2289476 A1 CA2289476 A1 CA 2289476A1
Authority
CA
Canada
Prior art keywords
alpha
tnf
molecule
modified
tnfa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002289476A
Other languages
English (en)
French (fr)
Inventor
Martin Roland Jensen
Soren Mouritsen
Henrik Elsner
Iben Dalum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affitech AS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2289476A1 publication Critical patent/CA2289476A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/144—Tumor necrosis factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002289476A 1997-04-15 1998-04-15 Modified tnf.alpha. molecules, dna encoding such modified tnf.alpha. molecules and vaccines comprising such modified tnf.alpha. molecules and dna Abandoned CA2289476A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DK0418/97 1997-04-15
DK41897 1997-04-15
US4418797P 1997-04-24 1997-04-24
US60/044,187 1997-04-24
PCT/DK1998/000157 WO1998046642A1 (en) 1997-04-15 1998-04-15 MODIFIED TNFα MOLECULES, DNA ENCODING SUCH MODIFIED TNFα MOLECULES AND VACCINES COMPRISING SUCH MODIFIED TNFα MOLECULES AND DNA

Publications (1)

Publication Number Publication Date
CA2289476A1 true CA2289476A1 (en) 1998-10-22

Family

ID=8093298

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002289476A Abandoned CA2289476A1 (en) 1997-04-15 1998-04-15 Modified tnf.alpha. molecules, dna encoding such modified tnf.alpha. molecules and vaccines comprising such modified tnf.alpha. molecules and dna

Country Status (29)

Country Link
US (1) US7118750B1 (OSRAM)
EP (1) EP0975668B1 (OSRAM)
JP (1) JP2001521386A (OSRAM)
KR (1) KR100522289B1 (OSRAM)
CN (1) CN1178955C (OSRAM)
AR (1) AR012427A1 (OSRAM)
AT (1) ATE326481T1 (OSRAM)
AU (1) AU743400B2 (OSRAM)
BR (1) BR9811462A (OSRAM)
CA (1) CA2289476A1 (OSRAM)
CZ (1) CZ9903657A3 (OSRAM)
DE (1) DE69834556T2 (OSRAM)
DK (1) DK0975668T3 (OSRAM)
EE (1) EE9900461A (OSRAM)
ES (1) ES2264569T3 (OSRAM)
HR (1) HRP980203B1 (OSRAM)
HU (1) HUP0001930A3 (OSRAM)
IL (1) IL132281A0 (OSRAM)
NO (1) NO995002L (OSRAM)
NZ (1) NZ337955A (OSRAM)
PL (1) PL194221B1 (OSRAM)
RU (1) RU2241715C2 (OSRAM)
SI (1) SI0975668T1 (OSRAM)
SK (1) SK285639B6 (OSRAM)
TR (1) TR199902562T2 (OSRAM)
TW (1) TW510921B (OSRAM)
UA (1) UA72440C2 (OSRAM)
WO (1) WO1998046642A1 (OSRAM)
ZA (1) ZA983148B (OSRAM)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
WO2000051637A1 (en) * 1999-03-02 2000-09-08 Centocor, Inc. ANTI-TNFα ANTIBODIES IN THERAPY OF ASTHMA
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
WO2000067777A1 (en) * 1999-05-07 2000-11-16 Biofan Pty Ltd A method of prophylaxis and treatment and agents useful therefor
SK722002A3 (en) 1999-07-20 2003-02-04 Pharmexa As Method for down-regulating GDF-8 activity
WO2001097837A1 (en) * 2000-06-21 2001-12-27 Ferring Bv Solubilised protein vaccines
WO2003075951A2 (en) * 2002-03-11 2003-09-18 Pharmexa A/S Novel application of vaccination against tnf-alpha
FR2844514B1 (fr) * 2002-09-16 2007-10-19 Neovacs Produit immunogene stable comprenant des heterocomplexes antigeniques, compositions les contenant et procede de preparation
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
MXPA05008156A (es) * 2003-02-01 2005-09-30 Neuralab Ltd Inmunizacion activa para generar anticuerpos para beta-a soluble.
MXPA06009805A (es) 2004-02-27 2007-04-02 Vaxconsulting Peptidos de interleucina 1 beta y factor de necrosis tumoral alfa y metodo de tratamiento utilizando los mismos.
PE20061329A1 (es) 2004-12-15 2006-12-08 Neuralab Ltd Anticuerpos ab humanizados para mejorar la cognicion
KR101465456B1 (ko) 2005-05-16 2014-11-27 애브비 바이오테크놀로지 리미티드 미란성 다발관절염의 치료를 위한 ｔｎｆ 억제제의 용도
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
KR20100084623A (ko) * 2007-09-25 2010-07-27 인터벳 인터내셔널 비.브이. 골관절염 치료용 백신
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
WO2011057099A2 (en) 2009-11-05 2011-05-12 The Uab Research Foundation Treating basal-like genotype cancers
US8703712B2 (en) 2010-03-18 2014-04-22 The Uab Research Foundation Targeting cancer stem cells with DR5 agonists
US8907053B2 (en) * 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
EP2462950A1 (en) 2010-12-08 2012-06-13 Neovacs Strongly inactivated and still highly immunogenic vaccine, and process of manufacturing thereof
CA2820837A1 (en) 2010-12-08 2012-06-14 Neovacs Strongly inactivated and still highly immunogenic vaccine and process of manufacturing thereof
CN102539778A (zh) * 2010-12-24 2012-07-04 北京义翘神州生物技术有限公司 一种检测人肿瘤坏死因子-α的酶联免疫试剂盒
JP2011201902A (ja) * 2011-05-19 2011-10-13 Wyeth Llc 可溶性Ａ−βに対する抗体を生成させるための能動免疫
CN103376327A (zh) * 2012-04-28 2013-10-30 通用电气公司 检测抗体或融合蛋白的浓度的方法
AU2016256876B2 (en) 2015-05-05 2021-02-04 Rubicon Biotechnology Llc Cancer immunotherapeutic
CN106279403B (zh) * 2016-08-16 2019-06-11 长春市海兰深生物医学技术有限公司 一种检测天然肺癌相关抗体的组合物、试剂盒和方法
CN106478802B (zh) * 2016-10-11 2019-08-09 浙江省人民医院 TNF-α蛋白B细胞表位，含此表位的多抗原肽及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3750056T2 (de) 1986-06-20 1995-04-06 Dainippon Pharmaceutical Co Polypeptid-Mutanten des menschlichen TNF und für diese Mutanten codierende DNS.
DE3843534A1 (de) * 1988-12-23 1990-07-12 Basf Ag Neue tnf-polypeptide
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
AU634379B2 (en) 1991-04-29 1993-02-18 Csl Limited Recombinant immunocastration vaccine
SE9102808L (sv) * 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
CA2119089A1 (en) 1993-03-29 1994-09-30 David Banner Tumor necrosis factor muteins
DK96493D0 (da) 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden

Also Published As

Publication number Publication date
TW510921B (en) 2002-11-21
HUP0001930A2 (hu) 2000-09-28
RU2241715C2 (ru) 2004-12-10
KR20010006416A (ko) 2001-01-26
HRP980203A2 (en) 1998-12-31
UA72440C2 (en) 2005-03-15
PL336295A1 (en) 2000-06-19
EE9900461A (et) 2000-06-15
AR012427A1 (es) 2000-10-18
ES2264569T3 (es) 2007-01-01
CN1252809A (zh) 2000-05-10
HUP0001930A3 (en) 2001-10-29
AU743400B2 (en) 2002-01-24
ZA983148B (en) 1999-10-15
ATE326481T1 (de) 2006-06-15
JP2001521386A (ja) 2001-11-06
SK285639B6 (sk) 2007-05-03
PL194221B1 (pl) 2007-05-31
CZ9903657A3 (cs) 2001-09-12
TR199902562T2 (xx) 2000-02-21
AU7030398A (en) 1998-11-11
DE69834556T2 (de) 2007-05-10
NO995002L (no) 1999-12-15
US7118750B1 (en) 2006-10-10
BR9811462A (pt) 2000-09-12
HRP980203B1 (en) 2003-04-30
IL132281A0 (en) 2001-03-19
NO995002D0 (no) 1999-10-14
EP0975668A1 (en) 2000-02-02
SK140999A3 (en) 2000-06-12
CN1178955C (zh) 2004-12-08
WO1998046642A1 (en) 1998-10-22
NZ337955A (en) 2000-09-29
DE69834556D1 (de) 2006-06-22
HK1022918A1 (en) 2000-08-25
KR100522289B1 (ko) 2005-10-19
DK0975668T3 (da) 2006-09-25
EP0975668B1 (en) 2006-05-17
SI0975668T1 (sl) 2007-02-28

Similar Documents

Publication Publication Date Title
AU743400B2 (en) Modified TNFalpha molecules, DNA encoding such modified TNFalpha molecules and vaccines comprising such modified TNFalpha molecules and DNA
AU754971B2 (en) Method for down-regulating osteoprotegerin ligand activity
CA2393659C (en) Multimeric forms of tnf superfamily ligands
HUP0101521A2 (hu) A Mycobacterium tuberculosis antigének fúziós fehérjéi és felhasználásuk
US20070184023A1 (en) Method for down-regulation of vegf
CA2467052A1 (en) Immunogenic mimetics of multimer proteins with promiscuous t cell epitope inserts
JP2005535353A (ja) Ｃ４ｂｐスカフォールドを使用した、多量体融合タンパク質の産生
EP0706574A1 (en) Methods for peptide synthesis and purification
ZA200509031B (en) Immunogenic human TNF alpha analogues with reduced cytotoxicity and methods of their preparation
JP3251592B2 (ja) Ｉｌ―１６活性を有するプロセスされたポリペプチド、それらの製法、及びそれらの使用
US20060222624A1 (en) Detoxified TNF and method of preparing
HK1022918B (en) Modified tnfalpha molecules, dna encoding such modified tnfalpha molecules and vaccines comprising such modified tnfalpha molecules and dna
JPH0380096A (ja) モチリン様ポリペプチドの製法並びにそのための組換えｄｎａ及び発現用プラスミド
MXPA99009394A (es) Moleculas de tnfa modificadas, adn que modifica tales moleculas de tnfa modificadas y vacunas que comprenden tales moleculas tnfa modificadas y adn
KR20040068561A (ko) 카르복시펩티다아제 ｇ2에서의 ｔ-세포 에피토프
JPS61155400A (ja) インタ−フエロンの精製方法

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued